Kidney Week

Abstract: SA-PO0518

Continuous Glucose Monitoring and Survival in a National CKD Cohort

Session Information

• CKD: Clinical - Therapies, CKM Health, Special Populations, and More
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 2202 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

• You, Amy Seungsook, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States

Amy Seungsook You, MS

• Kalantar-Zadeh, Kamyar, Harbor-UCLA Medical Center, Torrance, California, United States

Kamyar Kalantar-Zadeh, MD, DrMed, PhD, MPH, FASN

• Narasaki, Yoko, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States

Yoko Narasaki, MS, PhD

• Zisman-Ilani, Yaara, Temple University, Philadelphia, Pennsylvania, United States

Yaara Zisman-Ilani, MA, PhD

• Klonoff, David Charles, Diabetes Technology Society, Burlingame, California, United States

David Charles Klonoff, MD

• Kovesdy, Csaba P., The University of Tennessee Health Science Center, Memphis, Tennessee, United States

Csaba P. Kovesdy, MD, FASN

• Hanna, Ramy Magdy, University of California Irvine, Irvine, California, United States

Ramy Magdy Hanna, MD, FASN

• Ahdoot, Rebecca S., University of California Irvine, Irvine, California, United States

Rebecca S. Ahdoot

• Shah, Anuja P., Harbor-UCLA Medical Center, Torrance, California, United States

Anuja P. Shah, MD

• Dukkipati, Ramanath B., Harbor-UCLA Medical Center, Torrance, California, United States

Ramanath B. Dukkipati, MD

• Dai, Tiane, Harbor-UCLA Medical Center, Torrance, California, United States

Tiane Dai, MD, PhD

• Daza Aguilar, Andrea C., University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States

Andrea C. Daza Aguilar

• Novoa Vargas, Alejandra, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States

Alejandra Novoa Vargas, MPH

• Nguyen, Danh V., University of California Irvine, Irvine, California, United States

Danh V. Nguyen, PhD

• Rhee, Connie, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States

Connie Rhee, MD, MS

Background

In the CKD population, diabetes mellitus (DM) and dysglycemia are highly prevalent and are associated with adverse clinical outcomes, including CV disease and death. Conventional glycemic measures (HbA1c, capillary glucose) incompletely capture dynamic glucose fluctuations that are common in CKD. Continuous glucose monitoring (CGM), a wearable technology that provides real-time glycemic assessment with reduced patient burden, has been shown in non-CKD patients to improve glycemic control and reduce hypoglycemia. However, the relationship between CGM use and survival in the CKD population remains poorly understood.

Methods

We compared survival among patients with incident CKD (≥2 eGFRs <60 separated by ≥90 days over 1/1/18-12/31/24) and DM with incident CGM use vs. non-use from the OptumLabs^® Data Warehouse (OLDW), which contains de-identified administrative claims, including medical/pharmacy claims and enrollment records for commercial/Medicare enrollees, and EHR data. Patients with CGM use vs. non-CGM use were matched by propensity score (PS) in a 1:1 ratio to address confounding by indication, and were followed for the outcome of all-cause mortality from the 2^nd (index) eGFR <60 through 12/31/2025 using unadjusted and doubly-adjusted Cox models.

Results

There were 21,304 matched pairs of patients with incident CGM use and with non-CGM use (total N = 42,608) after PS matching. Compared with non-CGM use, CGM use was associated with lower risk of death in unadjusted PS-matched analyses: HR (95%CI) 0.56 (0.53, 0.58). These findings were robust in the doubly-adjusted PS-matched model: HR (95%CI) 0.53 (0.50, 0.55) (Figure).

Conclusion

In a national cohort of CKD patients with DM, CGM use was associated with better survival vs. non-CGM use. Further studies are needed to determine underlying mechanisms, as well as the impact of CGM on other hard endpoints and patient-centered outcomes in CKD.

Funding

• NIDDK Support